Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

NMS Labs Appoints Dan Monahan as President and Chief Executive Officer


NMS Labs, one of the nation's leading forensic science and bioanalytical toxicology laboratories, announced today that Dan T. Monahan is the now President and Chief Executive Officer of the Company. Mr. Monahan will build upon NMS Labs' success and provide leadership in advancing the organization's strategic growth and expansion initiatives.

Dan Monahan has extensive experience in leadership positions during his past 9 years with Thermo Fisher Scientific. Most recently he was Vice President and General Manager within Unity Lab Services, where he led a $200M global services business line with 1100 employees. Prior to that role, Mr. Monahan was the Vice President and General Manager of a $1B global distribution business. Earlier in his career, he held positions in various functional areas including commercial operations, marketing, business development, finance, and product development.

Mr. Monahan earned an MBA with distinction from Harvard Business School, and a Master of Engineering and Bachelor of Science in Chemical Engineering from Illinois Institute of Technology.

"It is a great honor and incredibly humbling to have the opportunity to lead a successful, purpose-driven organization," said Mr. Monahan. "NMS Labs has tremendous expertise and is poised for growth in the industries we serve. When you couple that with our accomplished colleagues who have a passion for the work they perform, we will achieve true success together."

"It is with great pleasure that we announce Daniel Monahan as President and CEO of NMS Labs. He has a strong analytical mindset and compelling vision for the future of our company. We are confident in his ability to build upon the many successes NMS Labs has already achieved and look forward to his leadership in advancing our strategic growth initiatives," stated company owners Michael F. Rieders and Eric F. Rieders. "With the commitment to the values and mission of our 50-year-old business and infusion of new leadership, we look forward to an ever-brighter future."

ABOUT NMS LABS

NMS Labs is a leading bioanalytical toxicology and forensic sciences laboratory providing esoteric clinical and forensic services to physicians, attorneys, the criminal justice system, clinical reference labs, pharmaceutical companies, and consumer products manufacturers. As part of our services, NMS Labs' professionals interpret our laboratory testing results to resolve client-specific issues and provide expert witness testimony and consulting support for both civil and criminal judicial proceedings.

Website: www.nmslabs.com

Follow NMS Labs on Social Media

LinkedIn ? https://linkedin.com/company/nms-labs

Facebook ? https://www.facebook.com/NMSLABS/

Twitter ? https://twitter.com/NMS_Labs


These press releases may also interest you

at 16:20
The Board of Directors of Revvity , today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity ...

at 16:20
Edwards Lifesciences today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales...

at 16:16
A functional assessment of Bacillus subtilis PLSSC (SEBtilistm) demonstrated its antimicrobial activity and capability to offer health benefits through industrial processing and the digestion process, showing its value-add in functional foods,...

at 16:15
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 first quarter earnings conference call on Thursday, May 9, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for...

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...

at 16:05
Stevanato Group S.p.A. , a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first...



News published on and distributed by: